Frazier Healthcare Partners
No summary available yet.
Frazier is the grown-up at the healthcare investing table. They've been doing this since 1991 and actually know what they're talking about when it comes to healthcare trends. Their Executive-in-Residence model is legit - they don't just write checks, they pair you with seasoned healthcare operators who've done it before. The Center of Excellence isn't just fancy marketing - it's a real 22-person team providing actual operational support. However, they're institutional money with institutional timelines, so don't expect scrappy startup energy. They want to see proven business models with clear paths to profitability, not moonshot science experiments.
- —Best for: Healthcare services companies with proven revenue looking to scale via M&A
- —Watch out for: They move deliberately - not for founders who need quick decisions or love chaos
- —Known for: Actually understanding healthcare operations and bringing real industry expertise
Frazier focuses on thesis-driven investing with proven healthcare executives, identifying long-term secular trends in healthcare and pairing those insights with their Executive-in-Residence program to build category-leading companies. They target profitable healthcare companies that improve quality, accessibility, and affordability of healthcare while bending the cost curve.
Middle-market growth buyouts and life sciences venture. Growth Buyout team targets profitable healthcare services companies with $5-50M EBITDA, writing $30-350M equity checks. Life Sciences team invests across company creation, venture rounds, and public markets in therapeutics addressing unmet medical needs.
One of the key architects of Frazier's thesis-driven approach. Frequently quoted on healthcare transformation trends and value-based medicine. Known for deep operational expertise and identifying secular trends before they hit the broader market.
Focuses on the Growth Buyout strategy and has been instrumental in scaling the firm's investment approach. Known for developing the firm's Executive-in-Residence model and building out their Center of Excellence capabilities.
Key leader on both Growth Buyout and Life Sciences teams. Has extensive experience managing public biotech investments and has been with the firm through multiple fund cycles.
Co-leads the Life Sciences strategy with deep biotech expertise. Has been instrumental in building Frazier's reputation in therapeutics and managing their public life sciences fund.
Recently promoted and leads the firm's New York office expansion. Focuses on building out their East Coast presence and deal sourcing capabilities.
Have a specific question about Frazier Healthcare Partners?
Ask Bernie →